Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | DBH | P09172 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.47 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28396648 | 0.87 | TSHR (0.52) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL34953 | 0.86 | TSHR (0.70) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL7945435 | 0.86 | GAA (0.59) | ALDH1A1KDM4EDBHGAARECQL | |
| SCHEMBL2307365 | 0.86 | TSHR (0.50) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL6164364 | 0.85 | TSHR (0.53) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL10941453 | 0.84 | TSHR (0.67) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL29966404 | 0.84 | TSHR (0.67) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| SCHEMBL9943503 | 0.84 | TSHR (0.67) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| Lithium SCHEMBL29634258 | 0.84 | TSHR (0.67) | TSHRLOXL2CYP4F2CYP4A11RAB9A | |
| Potassium SCHEMBL30190417 | 0.84 | TSHR (0.67) | TSHRLOXL2CYP4F2CYP4A11RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20230348369-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-10-06 | — | — | US | disclosed |
| US-9333202-B2 | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2016-05-10 | — | — | US | disclosed |
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2015-05-07 | — | — | US | disclosed |
| EP-2818237-A1 | Surface active agent and preparation thereof | Chemstream BVBA (BE) | 2014-12-31 | — | — | EP | disclosed |
| EP-2818237-A1 | Surface active agent and preparation thereof | Chemstream BVBA (BE) | 2014-12-31 | — | — | EP | disclosed |
| US-8835441-B2 | Heterobicyclic metalloprotease inhibitors | AMGEN INC. (US) | 2014-09-16 | — | — | US | disclosed |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2012-01-19 | — | — | US | disclosed |
| US-8093241-B2 | Acid amide derivatives, process for their production and pesticides containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-01-10 | — | — | US | disclosed |
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7683096-B2 | Acid amide derivatives, process for producing these, and pest control agent containing these | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2010-03-23 | — | — | US | disclosed |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | ISHIHARA SANGYO KAISHA LTD. (JP) | 2004-12-16 | — | — | US | disclosed |
| EP-1428817-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR PRODUCING THESE, AND PEST CONTROL AGENT CONTAINING THESE | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2004-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150126494-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | TSHR 161/4885LOXL2 567/4885CYP4F2 4266/4885 |
| US-20100093707-A1 | ACID AMIDE DERIVATIVES, PROCESS FOR THEIR PRODUCTION AND PESTICIDES CONTAINING THEM | NAA15, SAP18, CYP2C18 | TSHR 132/4885LOXL2 4046/4885CYP4F2 916/4885 |
| US-20040254237-A1 | Acid amide derivatives, process for producing these, and pest agent containing these | NAA15, CBR3, CBR1 | TSHR 210/4885LOXL2 2392/4885CYP4F2 1249/4885 |
| US-20090312312-A1 | Heterobicyclic Metalloprotease Inhibitors | MMP13, TIMP3, MMP3 | TSHR 4659/4885LOXL2 1949/4885CYP4F2 2810/4885 |
| US-20120015920-A1 | HETEROBICYCLIC METALLOPROTEASE INHIBITORS | MMP13, TIMP3, MMP3 | TSHR 4659/4885LOXL2 1949/4885CYP4F2 2810/4885 |
| US-20230348369-A1 | NAMPT MODULATORS | NAMPT, NNT, NAPRT | TSHR 1050/4885LOXL2 4331/4885CYP4F2 1260/4885 |
| US-20160287607-A1 | NON-RETINOID ANTAGONISTS FOR TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND STARGARDT DISEASE | RBP4, RBP1, LRAT | TSHR 161/4885LOXL2 567/4885CYP4F2 4266/4885 |
| US-20070155738-A1 | Heterobicyclic metalloprotease inhibitors | MMP13, TIMP3, MMP3 | TSHR 4659/4885LOXL2 1949/4885CYP4F2 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.